1 / 8

3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 Study M12-999

Phase 2. Liver Transplantation. Treatment Naïve and Treatment Experienced. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 Study M12-999. Kwo P, et al. 49 th EASL. April 2014. Abstract O114.

mariko-white
Download Presentation

3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 Study M12-999

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 Liver Transplantation Treatment Naïve and Treatment Experienced 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999 Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  2. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999: Study Design Source: Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  3. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999: Regimen 0 24 36 Week 3D + Ribavirin N = 34 SVR12 3D =Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): dosing managed per investigator discretion; most patients received 600-800 mg/day Source: Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  4. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999: Baseline Characteristics Source: Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  5. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999: Results 34/34 34/34 32/33 25/26 RVR = rapid virologic response; EOTR = end of treatment response; SVR = sustained virologic response Source: Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  6. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999: Adverse Events Source: Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  7. 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1Study M12-999: Conclusions Note: ABT-450/r = Paritaprevir-Ritonavir Source: Kwo P, et al. 49th EASL. April 2014. Abstract O114.

  8. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related